权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Chemical Optimization of c-Cbl Antagonists for Corneal Wound Healing

用于角膜伤口愈合的 c-Cbl 拮抗剂的化学优化

基本信息

批准号：
10557187
负责人：
BRIAN P. CERESA
金额：
$ 38.5万
依托单位：
UNIVERSITY OF LOUISVILLE
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-02-01 至 2025-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10557187
关键词：
Acceleration Address Advanced Development Affinity Anatomy Animal Model Antineoplastic Agents Bacteria Binding Biochemical Biological Assay Biology Biomedical Engineering Blindness Bypass Calorimetry Cell Proliferation Cell model Cetuximab Chemical Injury Chemical Structure Chemicals Complex Cornea Corneal Diseases Corneal Injury Data Development Diabetes Mellitus Disease Distress Drug Side Effects Drug usage EGF gene Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Epithelial Cells Epithelium Event Eye Eye Infections FDA approved Generations Goals Growth Factor Receptors Health care facility Homeostasis Human In Vitro Incidence Infection Investigation Laboratories Lead Ligands Light Lysosomes Maintenance Measures Mediating Membrane Mission Modeling Modification Molecular Operative Surgical Procedures Oryctolagus cuniculus Pain Patients Prevalence Primary Care Procedures Proliferating Proteins Public Health Reagent Receptor Signaling Recombinants Recurrence Research Retina Rodent Signal Transduction Structure Testing Therapeutic Therapeutic Agents Tissue Model Tissues Topical application Trauma Virus Vision Work antagonist cancer type cell growth cell motility cell replacement therapy corneal epithelial wound healing corneal epithelium corneal surgery cytokine cytotoxicity desensitization drug development drug-like compound experience heat injury improved in silico in vivo inhibitor innovation interest knock-down limbal nanomolar novel novel therapeutics particle pharmacologic preservation prevent receptor restoration side effect stem cell replacement tissue culture trafficking ubiquitin-protein ligase wound healing

项目摘要

Project Summary An intact and fully differentiated corneal epithelium is critical for proper vision and to keep foreign objects (bacteria, viruses, small particles) out of the eye. However, damage to the corneal epithelium is one of the most common ocular problems presented in primary care facilities and arises from a variety of factors, including trauma, disease, and a side-effect of drugs. Despite the prevalence, discomfort, and potential for blindness associated with perturbation of the corneal epithelium, there are no FDA-approved agents that promote the restoration and homeostasis of this tissue. The long-term goal of our research is to develop new compounds that promote corneal epithelial wound healing and homeostasis. The overall objective of this application is to chemically optimize a recently identified c-Cbl antagonist to increase its affinity and potency, while decreasing cytotoxicity. To accomplish this, we will test the central hypothesis that compounds that disrupt EGFR:c-Cbl interactions will prevent EGFR ubiquitylation, divert the activated EGFR from the lysosome, and prolong EGFR signaling. Based on preliminary studies, this prolongs EGFR activity and increases the restoration and maintenance of corneal epithelium via cell migration, proliferation, and differentiation. The rationale for these studies is that knockdown of c-Cbl and inhibits EGFR ubiquitylation, prolongs EGFR activity, and enhances corneal epithelial wound healing. Following an in silico screen of 25,000,000 compounds, we have identified several lead compounds that bind c-Cbl and inhibit ligand-mediated EGFR ubiquitylation. We seek to develop the top compound into a therapeutic agent with the following specific aims. In Aim 1, we will structurally optimize our lead compound to increase its affinity for c-Cbl and disrupt EGFR:c-Cbl binding. Multiple rounds of chemical modifications to our lead compound will be used to identify new derivatives that bind recombinant c-Cbl with high affinity and disrupt EGFR:c-Cbl interactions. In Aim 2, we will test the highest affinity compounds for disruption of c-Cbl-mediated ubiquitylation and trafficking of the EGFR. The top candidates will be tested for their ability to block ligand-mediated EGFR ubiquitylation and lysosomal degradation, and if they prolong EGFR signaling in corneal epithelial cells. In Aim 3, we will determine whether inhibitors of EGFR ubiquitylation promote corneal epithelial wound healing. The top compounds will be assayed for corneal epithelial wound healing using in vitro, ex vivo, and in vivo assays. Our proposed studies are innovative, in our opinion, because we will by-pass the limitation of EGFR occupancy and target a novel protein (c-Cbl) and molecular mechanism (receptor desensitization). These studies are significant because accelerating re-epithelialization and homeostasis of compromised corneas will decrease patient distress, minimize infections, and reduce the incidence of blindness. Corneal epithelial homeostasis is a major public health issue with limited treatments. Our goal is to develop our lead compounds for the topical treatment of compromised corneal epithelium to restore tissue homeostasis.

项目总结